BPH (benign prostatic hyperplasia or prostate enlargement) is a common affliction of middle aged and older men. BPH is one of the most commonly diagnosed diseases in the male population. The condition can seriously impact the health and quality of life of middle aged and older men and leads to symptoms which can include weakened urinary flow, urinary urgency, frequency, nocturia, incontinence, incomplete emptying, straining, urinary tract infections, urinary retention and can lead to obstruction and more serious problems if untreated. It is estimated that 50% of men in their 50s have pathological signs of BPH and the majority of men in their 70s and 80s have some symptoms of BPH.
Nymox has developed a new treatment for BPH, Fexapotide Triflutate. More information about FT is available here.